MANIFESTATIONS  ||| S:0 E:15 ||| NNS
OF  ||| S:15 E:18 ||| IN
OXIDATIVE  ||| S:18 E:28 ||| NNP
STRESS  ||| S:28 E:35 ||| NNP
AND  ||| S:35 E:39 ||| CC
MOLECULAR  ||| S:39 E:49 ||| NNP
DAMAGES  ||| S:49 E:57 ||| NNP
IN  ||| S:57 E:60 ||| IN
OVARIAN  ||| S:60 E:68 ||| NNP
CANCER  ||| S:68 E:75 ||| NNP
TISSUE  ||| S:75 E:82 ||| NNP
Indices  ||| S:82 E:90 ||| NNP
of  ||| S:90 E:93 ||| IN
oxidative  ||| S:93 E:103 ||| JJ
stress  ||| S:103 E:110 ||| NN
are  ||| S:110 E:114 ||| VBP
recognized  ||| S:114 E:125 ||| VBN
molecular  ||| S:125 E:135 ||| JJ
markers  ||| S:135 E:143 ||| NN
and  ||| S:143 E:147 ||| CC
prognostic  ||| S:147 E:158 ||| JJ
criteria  ||| S:158 E:167 ||| NNS
for  ||| S:167 E:171 ||| IN
malignant  ||| S:171 E:181 ||| JJ
transformation  ||| S:181 E:196 ||| NN
of  ||| S:196 E:199 ||| IN
tissue ||| S:199 E:205 ||| NN
,  ||| S:205 E:207 ||| ,
but  ||| S:207 E:211 ||| CC
their  ||| S:211 E:217 ||| PRP$
value  ||| S:217 E:223 ||| NN
depends  ||| S:223 E:231 ||| VBZ
on  ||| S:231 E:234 ||| IN
the  ||| S:234 E:238 ||| DT
type  ||| S:238 E:243 ||| NN
of  ||| S:243 E:246 ||| IN
tumor  ||| S:246 E:252 ||| NN
and  ||| S:252 E:256 ||| CC
the  ||| S:256 E:260 ||| DT
stage  ||| S:260 E:266 ||| NN
of  ||| S:266 E:269 ||| IN
its  ||| S:269 E:273 ||| PRP$
development ||| S:273 E:284 ||| NN
.  ||| S:284 E:286 ||| .
The  ||| S:286 E:290 ||| DT
goal  ||| S:290 E:295 ||| NN
of  ||| S:295 E:298 ||| IN
this  ||| S:298 E:303 ||| DT
study  ||| S:303 E:309 ||| NN
was  ||| S:309 E:313 ||| VBD
to  ||| S:313 E:316 ||| TO
clarify  ||| S:316 E:324 ||| VB
the  ||| S:324 E:328 ||| DT
relationship  ||| S:328 E:341 ||| NN
between  ||| S:341 E:349 ||| IN
the  ||| S:349 E:353 ||| DT
characteristics  ||| S:353 E:369 ||| NN
of  ||| S:369 E:372 ||| IN
the  ||| S:372 E:376 ||| DT
oxidative  ||| S:376 E:386 ||| JJ
stress  ||| S:386 E:393 ||| NN
system  ||| S:393 E:400 ||| NN
including  ||| S:400 E:410 ||| VBG
metal-associated  ||| S:410 E:427 ||| JJ
ones  ||| S:427 E:432 ||| NNS
and  ||| S:432 E:436 ||| CC
the  ||| S:436 E:440 ||| DT
cytotoxicity  ||| S:440 E:453 ||| JJ
manifestations  ||| S:453 E:468 ||| NNS
in  ||| S:468 E:471 ||| IN
neoplastically  ||| S:471 E:486 ||| NN
transformed  ||| S:486 E:498 ||| VBD
human  ||| S:498 E:504 ||| JJ
ovarian  ||| S:504 E:512 ||| JJ
tissue ||| S:512 E:518 ||| NN
.  ||| S:518 E:520 ||| .
The  ||| S:520 E:524 ||| DT
highest  ||| S:524 E:532 ||| JJS
level  ||| S:532 E:538 ||| NN
of  ||| S:538 E:541 ||| IN
Mn-superoxide  ||| S:541 E:555 ||| JJ
dismutase  ||| S:555 E:565 ||| JJ
activity  ||| S:565 E:574 ||| NN
( ||| S:574 E:575 ||| -LRB-
by  ||| S:575 E:578 ||| IN
630 ||| S:578 E:581 ||| CD
% ||| S:581 E:582 ||| NN
)  ||| S:582 E:584 ||| -RRB-
and  ||| S:584 E:588 ||| CC
metallothionein  ||| S:588 E:604 ||| JJ
protein  ||| S:604 E:612 ||| NN
( ||| S:612 E:613 ||| -LRB-
MT ||| S:613 E:615 ||| NNP
,  ||| S:615 E:617 ||| ,
100 ||| S:617 E:620 ||| CD
% ||| S:620 E:621 ||| NN
)  ||| S:621 E:623 ||| -RRB-
has  ||| S:623 E:627 ||| VBZ
been  ||| S:627 E:632 ||| VBN
estimated  ||| S:632 E:642 ||| VBN
for  ||| S:642 E:646 ||| IN
the  ||| S:646 E:650 ||| DT
first  ||| S:650 E:656 ||| JJ
time  ||| S:656 E:661 ||| NN
in  ||| S:661 E:664 ||| IN
malignant  ||| S:664 E:674 ||| JJ
ovarian  ||| S:674 E:682 ||| JJ
tissue  ||| S:682 E:689 ||| NN
compared  ||| S:689 E:698 ||| VBN
to  ||| S:698 E:701 ||| TO
normal  ||| S:701 E:708 ||| JJ
ovarian  ||| S:708 E:716 ||| JJ
tissue ||| S:716 E:722 ||| NN
.  ||| S:722 E:724 ||| .
The  ||| S:724 E:728 ||| DT
researchers  ||| S:728 E:740 ||| NNS
have  ||| S:740 E:745 ||| VBP
also  ||| S:745 E:750 ||| RB
found  ||| S:750 E:756 ||| VBD
a  ||| S:756 E:758 ||| DT
much  ||| S:758 E:763 ||| RB
higher  ||| S:763 E:770 ||| JJR
level  ||| S:770 E:776 ||| NN
of  ||| S:776 E:779 ||| IN
oxy-radical  ||| S:779 E:791 ||| JJ
formation  ||| S:791 E:801 ||| NN
( ||| S:801 E:802 ||| -LRB-
by  ||| S:802 E:805 ||| IN
332 ||| S:805 E:808 ||| CD
% ||| S:808 E:809 ||| NN
) ||| S:809 E:810 ||| -RRB-
,  ||| S:810 E:812 ||| ,
a  ||| S:812 E:814 ||| DT
lower  ||| S:814 E:820 ||| JJR
activity  ||| S:820 E:829 ||| NN
of  ||| S:829 E:832 ||| IN
catalase  ||| S:832 E:841 ||| NNS
( ||| S:841 E:842 ||| -LRB-
by  ||| S:842 E:845 ||| IN
49 ||| S:845 E:847 ||| CD
% ||| S:847 E:848 ||| NN
)  ||| S:848 E:850 ||| -RRB-
and  ||| S:850 E:854 ||| CC
a  ||| S:854 E:856 ||| DT
lower  ||| S:856 E:862 ||| JJR
level  ||| S:862 E:868 ||| NN
of  ||| S:868 E:871 ||| IN
reduced  ||| S:871 E:879 ||| JJ
glutathione  ||| S:879 E:891 ||| NNS
( ||| S:891 E:892 ||| -LRB-
by  ||| S:892 E:895 ||| IN
46 ||| S:895 E:897 ||| CD
% ||| S:897 E:898 ||| NN
)  ||| S:898 E:900 ||| -RRB-
and  ||| S:900 E:904 ||| CC
its  ||| S:904 E:908 ||| PRP$
redox  ||| S:908 E:914 ||| JJ
index  ||| S:914 E:920 ||| NN
( ||| S:920 E:921 ||| -LRB-
0.84  ||| S:921 E:926 ||| CD
versus  ||| S:926 E:933 ||| CD
0.89  ||| S:933 E:938 ||| CD
in  ||| S:938 E:941 ||| IN
the  ||| S:941 E:945 ||| DT
control ||| S:945 E:952 ||| NN
)  ||| S:952 E:954 ||| -RRB-
in  ||| S:954 E:957 ||| IN
tumor  ||| S:957 E:963 ||| NN
tissue ||| S:963 E:969 ||| NN
.  ||| S:969 E:971 ||| .
Under  ||| S:971 E:977 ||| IN
the  ||| S:977 E:981 ||| DT
relatively  ||| S:981 E:992 ||| RB
stable  ||| S:992 E:999 ||| JJ
content  ||| S:999 E:1007 ||| NN
of  ||| S:1007 E:1010 ||| IN
zinc ||| S:1010 E:1014 ||| NN
,  ||| S:1014 E:1016 ||| ,
copper  ||| S:1016 E:1023 ||| NN
and  ||| S:1023 E:1027 ||| CC
cadmium  ||| S:1027 E:1035 ||| NN
in  ||| S:1035 E:1038 ||| IN
MTs ||| S:1038 E:1041 ||| NNP
,  ||| S:1041 E:1043 ||| ,
the  ||| S:1043 E:1047 ||| DT
content  ||| S:1047 E:1055 ||| NN
of  ||| S:1055 E:1058 ||| IN
zinc  ||| S:1058 E:1063 ||| NN
and  ||| S:1063 E:1067 ||| CC
especially  ||| S:1067 E:1078 ||| RB
copper  ||| S:1078 E:1085 ||| NN
in  ||| S:1085 E:1088 ||| IN
a  ||| S:1088 E:1090 ||| DT
form  ||| S:1090 E:1095 ||| NN
non-binding  ||| S:1095 E:1107 ||| JJ
with  ||| S:1107 E:1112 ||| IN
MTs  ||| S:1112 E:1116 ||| NNP
was  ||| S:1116 E:1120 ||| VBD
significantly  ||| S:1120 E:1134 ||| RB
lower  ||| S:1134 E:1140 ||| JJR
in  ||| S:1140 E:1143 ||| IN
the  ||| S:1143 E:1147 ||| DT
malignant  ||| S:1147 E:1157 ||| JJ
tissue  ||| S:1157 E:1164 ||| NN
compared  ||| S:1164 E:1173 ||| VBN
to  ||| S:1173 E:1176 ||| TO
normal  ||| S:1176 E:1183 ||| JJ
one  ||| S:1183 E:1187 ||| NN
while  ||| S:1187 E:1193 ||| IN
the  ||| S:1193 E:1197 ||| DT
content  ||| S:1197 E:1205 ||| NN
of  ||| S:1205 E:1208 ||| IN
cadmium  ||| S:1208 E:1216 ||| NN
was  ||| S:1216 E:1220 ||| VBD
higher ||| S:1220 E:1226 ||| JJR
.  ||| S:1226 E:1228 ||| .
A  ||| S:1228 E:1230 ||| DT
discriminant  ||| S:1230 E:1243 ||| JJ
analysis  ||| S:1243 E:1252 ||| NN
of  ||| S:1252 E:1255 ||| IN
all  ||| S:1255 E:1259 ||| DT
definable  ||| S:1259 E:1269 ||| JJ
parameters  ||| S:1269 E:1280 ||| NNS
revealed  ||| S:1280 E:1289 ||| VBD
that  ||| S:1289 E:1294 ||| IN
the  ||| S:1294 E:1298 ||| DT
higher  ||| S:1298 E:1305 ||| JJR
content  ||| S:1305 E:1313 ||| NN
of  ||| S:1313 E:1316 ||| IN
the  ||| S:1316 E:1320 ||| DT
products  ||| S:1320 E:1329 ||| NNS
of  ||| S:1329 E:1332 ||| IN
oxidative  ||| S:1332 E:1342 ||| JJ
destruction  ||| S:1342 E:1354 ||| NN
of  ||| S:1354 E:1357 ||| IN
proteins ||| S:1357 E:1365 ||| NNS
,  ||| S:1365 E:1367 ||| ,
lipids ||| S:1367 E:1373 ||| NN
,  ||| S:1373 E:1375 ||| ,
fragmented  ||| S:1375 E:1386 ||| JJ
DNA  ||| S:1386 E:1390 ||| NN
and  ||| S:1390 E:1394 ||| CC
the  ||| S:1394 E:1398 ||| DT
activity  ||| S:1398 E:1407 ||| NN
of  ||| S:1407 E:1410 ||| IN
cathepsin  ||| S:1410 E:1420 ||| JJ
D ||| S:1420 E:1421 ||| NNP
,  ||| S:1421 E:1423 ||| ,
especially  ||| S:1423 E:1434 ||| RB
in  ||| S:1434 E:1437 ||| IN
its  ||| S:1437 E:1441 ||| PRP$
free  ||| S:1441 E:1446 ||| JJ
form  ||| S:1446 E:1451 ||| NN
( ||| S:1451 E:1452 ||| -LRB-
by  ||| S:1452 E:1455 ||| IN
235 ||| S:1455 E:1458 ||| CD
% ||| S:1458 E:1459 ||| NN
) ||| S:1459 E:1460 ||| -RRB-
,  ||| S:1460 E:1462 ||| ,
are  ||| S:1462 E:1466 ||| VBP
the  ||| S:1466 E:1470 ||| DT
main  ||| S:1470 E:1475 ||| JJ
characteristic  ||| S:1475 E:1490 ||| JJ
signs  ||| S:1490 E:1496 ||| NNS
of  ||| S:1496 E:1499 ||| IN
malignant  ||| S:1499 E:1509 ||| JJ
ovarian  ||| S:1509 E:1517 ||| JJ
tissue ||| S:1517 E:1523 ||| NN
.  ||| S:1523 E:1525 ||| .
